Loading company
SI-Bone, Inc.
SIBN · Nasdaq · ·
Next earnings: November 9, 2026
$19.15+2.1%Sep 29 close
- 1M
- -0.3%
- 6M
- +55.9%
- 1Y
- +30.1%
- 5Y
- -17.8%
SIBN · Nasdaq · ·
Next earnings: November 9, 2026
$19.15+2.1%Sep 29 close
SI-Bone, Inc. is scheduled to report next on November 9, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $56M | $48.6M | +15.18% |
| Profit | -$4.1M | -$6.2M | +33.55% |
| Profit per share | -$0.09 | -$0.14 | +35.71% |
| Free Cash Flow | -$768K | -$1.9M | +60.12% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our accelerating growth and expanding profitability reinforces our conviction in the demand for our superior platform technologies and the significant runway ahead,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Inc. SI-BONE (NASDAQ: SIBN) is a global leader in developing procedural solutions to address clinical challenges associated with compromised bone. With expertise in biomechanical design and anatomy specific innovation, SI-BONE has built a technology platform with market-leading applications centered on the spinopelvic anatomy. SI-BONE continues to leverage the deep experience in addressing the challenges of low-density bone in the sacrum to develop unique technologies that are targeting new clinical adjacencies to help improve outcomes for patients with compromised bone. Since 2009, SI-BONE has supported physicians in performing over 150,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 190 peer reviewed publications. For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com. SI-BONE®, iFuse Bedrock Granite®, iFuse TORQ® and iFuse TORQ TNT® are registered trademarks of SI-BONE, Inc. All other marks referenced herein are property of their respective owners.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from SI-Bone, Inc.’s Item 2.02 8-K filed August 3, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
SI-Bone, Inc. has no earnings call transcript available.